Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

Author:

Berge M.ORCID,Giraud J. S.,De Percin S.,Puszkiel A.,Thomas-Schoemann A.,Blanchet B.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Reference12 articles.

1. Farge D, Frere C, Connors JM, Khorana A, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347

2. Use of anti-factor Xa levels in cancer patients taking direct oral anticoagulants. In: ISTH Congr. Abstr. https://abstracts.isth.org/abstract/use-of-anti-factor-xa-levels-in-cancer-patients-taking-direct-oral-anticoagulants/. Accessed 24 Feb 2023

3. Delavenne X, Mismetti P, Basset T (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 78–79:150–153

4. Mavri A, Vene N, Božič-Mijovski M, Miklic M, Soderblom L, Pohanka A et al (2021) Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep 11:13908

5. Velev M, Puszkiel A, Blanchet B, De Percin S, Delanoy N, Medioni J et al (2021) Association between olaparib exposure and early toxicity in BRCA-mutated ovarian cancer patients: results from a retrospective multicenter study. Pharm Basel Switz 14:804

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3